JP2017537969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537969A5 JP2017537969A5 JP2017532678A JP2017532678A JP2017537969A5 JP 2017537969 A5 JP2017537969 A5 JP 2017537969A5 JP 2017532678 A JP2017532678 A JP 2017532678A JP 2017532678 A JP2017532678 A JP 2017532678A JP 2017537969 A5 JP2017537969 A5 JP 2017537969A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- protecting group
- formula
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000006239 protecting group Chemical group 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- -1 1-methyl-1H-pyrazol-4-yl Chemical group 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 4
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229910002483 Cu Ka Inorganic materials 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 239000012351 deprotecting agent Substances 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000022244 formylation Effects 0.000 claims description 2
- 238000006170 formylation reaction Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 22
- 0 *[C@@]1[C@@](*c(nc(c(C(N2)=O)c3C2O)Cl)c3F)CCCC1 Chemical compound *[C@@]1[C@@](*c(nc(c(C(N2)=O)c3C2O)Cl)c3F)CCCC1 0.000 description 1
- OJKXBPMNEIRBIC-UHFFFAOYSA-N OC(c(c1c(nc2F)Cl)c2F)NC1=O Chemical compound OC(c(c1c(nc2F)Cl)c2F)NC1=O OJKXBPMNEIRBIC-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020080282A JP6974534B2 (ja) | 2014-12-18 | 2020-04-30 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2021180105A JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462093564P | 2014-12-18 | 2014-12-18 | |
| US62/093,564 | 2014-12-18 | ||
| US201562115223P | 2015-02-12 | 2015-02-12 | |
| US62/115,223 | 2015-02-12 | ||
| US201562180222P | 2015-06-16 | 2015-06-16 | |
| US62/180,222 | 2015-06-16 | ||
| PCT/IB2015/002489 WO2016097862A2 (en) | 2014-12-18 | 2015-12-17 | Solid state forms of fused heteroaromatic pyrrolidinones |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080282A Division JP6974534B2 (ja) | 2014-12-18 | 2020-04-30 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537969A JP2017537969A (ja) | 2017-12-21 |
| JP2017537969A5 true JP2017537969A5 (enExample) | 2019-02-14 |
| JP6778195B2 JP6778195B2 (ja) | 2020-10-28 |
Family
ID=55299676
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532678A Active JP6778195B2 (ja) | 2014-12-18 | 2015-12-17 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2020080282A Expired - Fee Related JP6974534B2 (ja) | 2014-12-18 | 2020-04-30 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2021180105A Pending JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080282A Expired - Fee Related JP6974534B2 (ja) | 2014-12-18 | 2020-04-30 | 縮合複素芳香族ピロリジノンの固体状態形態 |
| JP2021180105A Pending JP2022017477A (ja) | 2014-12-18 | 2021-11-04 | 縮合複素芳香族ピロリジノンの固体状態形態 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10676473B2 (enExample) |
| EP (2) | EP3677582B1 (enExample) |
| JP (3) | JP6778195B2 (enExample) |
| KR (1) | KR102037502B1 (enExample) |
| CN (1) | CN107108609B (enExample) |
| AU (1) | AU2015365580B2 (enExample) |
| BR (1) | BR112017013149B1 (enExample) |
| CA (1) | CA2970864C (enExample) |
| CL (1) | CL2017001561A1 (enExample) |
| CO (1) | CO2017005910A2 (enExample) |
| CR (1) | CR20170249A (enExample) |
| DK (1) | DK3233857T3 (enExample) |
| DO (1) | DOP2017000130A (enExample) |
| EA (1) | EA032291B1 (enExample) |
| EC (1) | ECSP17038100A (enExample) |
| ES (1) | ES2788454T3 (enExample) |
| GE (2) | GEP20197050B (enExample) |
| IL (1) | IL252941B (enExample) |
| MX (1) | MX373586B (enExample) |
| MY (1) | MY199935A (enExample) |
| NZ (1) | NZ732371A (enExample) |
| PE (1) | PE20171179A1 (enExample) |
| PH (1) | PH12017501123A1 (enExample) |
| PL (1) | PL3233857T3 (enExample) |
| SG (1) | SG11201701911QA (enExample) |
| TN (1) | TN2017000080A1 (enExample) |
| UA (1) | UA120632C2 (enExample) |
| WO (1) | WO2016097862A2 (enExample) |
| ZA (1) | ZA201701800B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3233857T3 (pl) * | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
| JP2019520419A (ja) * | 2016-07-13 | 2019-07-18 | 武田薬品工業株式会社 | 脾臓チロシンキナーゼ阻害剤と他の治療薬の併用 |
| AU2018350683A1 (en) | 2017-10-19 | 2020-04-02 | Bayer Animal Health Gmbh | Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals |
| WO2019088039A1 (en) | 2017-10-30 | 2019-05-09 | Takeda Pharmaceutical Company Limited | Treatment of acute myeloid leukemia |
| MY208604A (en) | 2018-12-14 | 2025-05-20 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Salt of syk inhibitor and crystalline form thereof |
| MX2021009521A (es) | 2019-02-07 | 2021-09-08 | Janssen Biotech Inc | Inhibidores de dihidroorotato deshidrogenasa. |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| CN114630822B (zh) | 2019-10-10 | 2024-10-01 | 詹森生物科技公司 | 联芳基二氢乳清酸脱氢酶抑制剂 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
| WO2022074534A1 (en) | 2020-10-05 | 2022-04-14 | Janssen Biotech, Inc. | Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents |
| CN115698005B (zh) * | 2020-12-18 | 2024-02-06 | 山东轩竹医药科技有限公司 | 稠环类AhR抑制剂 |
| AU2022274071A1 (en) | 2021-05-11 | 2024-01-04 | Janssen Pharmaceutica Nv | Combination therapies |
| KR20240006638A (ko) | 2021-05-11 | 2024-01-15 | 얀센 파마슈티카 엔브이 | 조합 요법 |
| KR102539612B1 (ko) | 2021-12-24 | 2023-06-02 | 엘에스일렉트릭(주) | IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템 |
| JP2025540759A (ja) | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ阻害剤及び少なくとも１つの他の治療剤を含む組み合わせ |
| JP2025540762A (ja) | 2022-11-30 | 2025-12-16 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ |
| AU2024400853A1 (en) | 2023-12-15 | 2026-05-28 | Ishihara Sangyo Kaisha, Ltd. | N-substituted oxy-2-aminothiazolecarboxamide compound or salt thereof and agricultural and horticultural fungicide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960372B1 (en) * | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| EP2516434B1 (en) | 2009-12-23 | 2015-05-27 | Takeda Pharmaceutical Company Limited | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| WO2012177714A1 (en) | 2011-06-22 | 2012-12-27 | Takeda Pharmaceutical Company Limited | Substituted 6-aza-isoindolin-1-one derivatives |
| WO2016048982A2 (en) * | 2014-09-24 | 2016-03-31 | Millennium Pharmaceuticals, Inc. | COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES |
| PL3233857T3 (pl) * | 2014-12-18 | 2020-07-27 | Takeda Pharmaceutical Company Limited | Stałe postacie skondensowanych heteroaromatycznych pirolidynonów |
-
2015
- 2015-12-17 PL PL15831150T patent/PL3233857T3/pl unknown
- 2015-12-17 MY MYPI2017702209A patent/MY199935A/en unknown
- 2015-12-17 CN CN201580068971.2A patent/CN107108609B/zh active Active
- 2015-12-17 GE GEAP201514545A patent/GEP20197050B/en unknown
- 2015-12-17 ES ES15831150T patent/ES2788454T3/es active Active
- 2015-12-17 CR CR20170249A patent/CR20170249A/es unknown
- 2015-12-17 NZ NZ732371A patent/NZ732371A/en not_active IP Right Cessation
- 2015-12-17 EA EA201791369A patent/EA032291B1/ru unknown
- 2015-12-17 KR KR1020177019929A patent/KR102037502B1/ko not_active Expired - Fee Related
- 2015-12-17 JP JP2017532678A patent/JP6778195B2/ja active Active
- 2015-12-17 TN TN2017000080A patent/TN2017000080A1/en unknown
- 2015-12-17 WO PCT/IB2015/002489 patent/WO2016097862A2/en not_active Ceased
- 2015-12-17 AU AU2015365580A patent/AU2015365580B2/en not_active Ceased
- 2015-12-17 CA CA2970864A patent/CA2970864C/en active Active
- 2015-12-17 PE PE2017000944A patent/PE20171179A1/es unknown
- 2015-12-17 BR BR112017013149-8A patent/BR112017013149B1/pt not_active IP Right Cessation
- 2015-12-17 US US14/973,180 patent/US10676473B2/en active Active
- 2015-12-17 GE GEAP201914545A patent/GEAP201914545A/en unknown
- 2015-12-17 DK DK15831150.6T patent/DK3233857T3/da active
- 2015-12-17 EP EP20156863.1A patent/EP3677582B1/en active Active
- 2015-12-17 MX MX2017007162A patent/MX373586B/es active IP Right Grant
- 2015-12-17 EP EP15831150.6A patent/EP3233857B1/en active Active
- 2015-12-17 SG SG11201701911QA patent/SG11201701911QA/en unknown
- 2015-12-17 UA UAA201707489A patent/UA120632C2/uk unknown
-
2017
- 2017-03-13 ZA ZA2017/01800A patent/ZA201701800B/en unknown
- 2017-05-31 DO DO2017000130A patent/DOP2017000130A/es unknown
- 2017-06-15 IL IL252941A patent/IL252941B/en active IP Right Grant
- 2017-06-15 CO CONC2017/0005910A patent/CO2017005910A2/es unknown
- 2017-06-15 CL CL2017001561A patent/CL2017001561A1/es unknown
- 2017-06-15 PH PH12017501123A patent/PH12017501123A1/en unknown
- 2017-06-16 EC ECIEPI201738100A patent/ECSP17038100A/es unknown
-
2020
- 2020-04-30 JP JP2020080282A patent/JP6974534B2/ja not_active Expired - Fee Related
- 2020-05-08 US US16/870,653 patent/US11352355B2/en not_active Expired - Fee Related
-
2021
- 2021-11-04 JP JP2021180105A patent/JP2022017477A/ja active Pending
-
2022
- 2022-12-23 US US18/088,286 patent/US20230348461A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022140637A (ja) | 結晶性（８Ｓ，９Ｒ）－５－フルオロ－８－（４－フルオロフェニル）－９－（１－メチル－１Ｈ－１，２，４－トリアゾール－５－イル）－８，９－ジヒドロ－２Ｈ－ピリド［４，３，２－ｄｅ］フタラジン－３（７Ｈ）－オントシレート塩 | |
| JP5385923B2 (ja) | Ｎ−複素環式カルベン白金誘導体、この調製、およびこの治療用途 | |
| JP2018531226A5 (enExample) | ||
| JP2018504429A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| ES2804595T3 (es) | Nuevos derivados de 1-(4-pirimidinil)-1H-pirrolo[3,2-c]piridina como inhibidores de NIK | |
| JP2014521726A (ja) | キナーゼ阻害剤多形体 | |
| JP2013520424A5 (enExample) | ||
| JP2020511467A5 (enExample) | ||
| AU2024203916A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| HUE025349T2 (en) | Hydroxamic acid derivatives | |
| HRP20201582T1 (hr) | Polimorf sik inhibitora | |
| JP2016504365A5 (enExample) | ||
| HRP20210149T1 (hr) | Derivati 8-[6-[3-(amino)propoksi]-3-piridil]-1-izopropil-imidazo[4,5-c]kinolin-2-ona kao selektivni modulatori ataxia telangiectasia mutacije (atm) kinaze za liječenje raka | |
| IL295978B2 (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| KR20170066473A (ko) | Ｎｉｋ 억제제로서의 신규 화합물 | |
| JP2016528242A5 (enExample) | ||
| JP2021530444A5 (enExample) | ||
| JP2020514344A5 (enExample) | ||
| JP6978002B2 (ja) | チエノ−ピリミジン誘導体およびその使用 | |
| JP6674027B2 (ja) | キナゾリン誘導体の結晶及びその調製方法 | |
| Xu et al. | Synthesis and crystal structures of C24-epimeric 20 (R)-ocotillol-type saponins | |
| Cloonan et al. | Synthesis and serotonin transporter activity of sulphur-substituted α-alkyl phenethylamines as a new class of anticancer agents | |
| Vranec et al. | Low-dimensional compounds containing bioactive ligands. Part III: Palladium (II) complexes with halogenated quinolin-8-ol derivatives | |
| CN110156841B (zh) | 一种Pt(IV)离子型配合物及其制备方法 |